Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rh...
April 25 2019 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led
biopharmaceutical company focused on immuno-inflammatory and
dermatological diseases, today announced that it has submitted an
Investigational New Drug (IND) Application to the U.S. Food and
Drug Administration (FDA) for ATI-450, an oral MK2 inhibitor, for
the treatment of rheumatoid arthritis (RA). If the IND is allowed
by the FDA, Aclaris plans to initiate a Phase 1 clinical trial of
ATI-450 in the second half of 2019.
“We are very pleased to have this IND under review by the FDA,”
said Dr. Neal Walker, President & Chief Executive Officer of
Aclaris. “We look forward to beginning the development of
ATI-450 as a potential treatment for rheumatoid arthritis and other
potential indications driven by TNFα, IL-1β, IL-6, or IL-8. We
believe there is an important need to provide additional treatment
options for rheumatoid arthritis to improve overall patient
care.”
ATI-450, an investigational medicine formerly known as CDD-450,
would be the first novel compound created by Confluence Discovery
Technologies, Inc., our indirect wholly owned subsidiary, to enter
the clinical phase of development. Aclaris plans to initiate a
Phase 1 single ascending dose study of safety, tolerance, and
pharmacokinetics followed by several cohorts of multiple ascending
doses. Aclaris is actively considering additional indications for
clinical testing in the future.
Dosed orally, ATI-450 is a novel, selective MK2
(mitogen-activated protein kinase-activated protein kinase 2;
MAPKAPK2) pathway inhibitor. MK2 is a key regulator of
pro-inflammatory mediators including TNFα, IL-1β, IL-6, IL-8 and
other essential pathogenic signals in chronic inflammatory and
autoimmune diseases, as well as in cancer. Selective MK2
pathway inhibitors are being investigated for their potential
ability to block inflammatory cytokine production and activity and,
thereby, restore balance to the body’s immune system. Selective MK2
pathway inhibitors are also being evaluated in cancer models for
their ability to block stromal inflammation and affect cell-cycle
checkpoint activity. MK2 pathway inhibitors have the
potential to treat patients with a variety of inflammatory and
autoimmune diseases, as well as cancer. As an oral drug candidate,
ATI-450 is being developed as a potential alternative to
anti-TNF/anti-IL-1 biologics.
About Rheumatoid Arthritis
RA is the most common form of autoimmune arthritis. It affects
more than 1.3 million Americans. About 75% of RA patients are
women, and 1–3% of women may get rheumatoid arthritis in their
lifetime. The disease most often begins between the ages of 30 and
50, and is a chronic disease which causes joint pain, stiffness,
swelling, and decreased movement of the joints. Small joints in the
hands and feet are most commonly affected, but RA can affect
organs, such as eyes, skin or lungs.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical
company committed to addressing the needs of people with
immuno-inflammatory and dermatological diseases who lack
satisfactory treatment options. The company’s diverse and
multi-stage portfolio includes two FDA-approved medicines, one
late-stage investigational medicine, and a pipeline powered by a
robust R&D engine exploring protein kinase regulation. Aclaris
Therapeutics’ active development programs focus on areas where
significant treatment gaps exist, such as common warts, alopecia
areata, and vitiligo. For additional information, please visit
www.aclaristx.com and follow Aclaris on LinkedIn or Twitter
@aclaristx.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
"believe", "expect", "may", "plan," "potential," "will," and
similar expressions, and are based on Aclaris' current beliefs and
expectations. These forward-looking statements include expectations
regarding the clinical development of ATI-450, including the timing
for initiation of planned clinical trials. These statements involve
risks and uncertainties that could cause actual results to differ
materially from those reflected in such statements. Risks and
uncertainties that may cause actual results to differ materially
include uncertainties inherent in the conduct of clinical trials,
Aclaris' reliance on third parties over which it may not always
have full control, and other risks and uncertainties that are
described in the Risk Factors section of Aclaris' Annual Report on
Form 10-K for the year ended December 31, 2018, and other filings
Aclaris makes with the U.S. Securities and Exchange Commission from
time to time. These documents are available under the "SEC filings”
section of the Investors page of Aclaris' website at
http://www.aclaristx.com. Any forward-looking statements speak only
as of the date of this press release and are based on information
available to Aclaris as of the date of this release, and Aclaris
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:Aclaris ContactMichael Tung, M.D.Senior
Vice President Corporate Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024